. Author manuscript; available in PMC: 2018 Nov 1.

Published in final edited form as: J Heart Lung Transplant. 2017 May 20;36(11):1243–1249. doi: 10.1016/j.healun.2017.05.023

Table 2. Baseline and 6-month post-implant KCCQ12-os and EQ-5D VAS.

	n	Baseline Mean ± SD	KCCQ12-os 6-Month Mean ± SD	Median Std Difference	Baseline Mean ± SD	EQ-5D VAS 6-Month Mean ± SD	Median Std Difference
All patients	1	36 ± 21	68 ± 20	1.6	45 ± 24	73 ± 20	1.0
	8
	8
	8
Patients with strokes	9	35 ± 21	62 ± 23	1.2	44 ± 24	69 ± 21	0.8
Patients with strokes	6	35 ± 21	62 ± 23	1.2	44 ± 24	69 ± 21	0.8
Patients with bleeding events	5	36 ± 22	67 ± 21	1.5	47 ± 25	73 ± 19	1.0
	9
	3
KCCQ12-os improvers	1	31 ± 18	72 ± 17	1.9	44 ± 24	75 ± 19	1.2
	5
	3
	9
Concordant patients	1	31 ± 19	72 ± 17	1.9	38 ± 21	78 ± 15	1.6
	2
	0
	5
Discordant patients	3	32 ± 17	72 ± 17	1.8	65 ± 22	63 ± 26	0.0
	3
	4

KCCQ12-os, Kansas City Cardiomyopathy Questionnaire-overall summary score; EQ-5D VAS, EuroQoL-5D Visual Analog Scale Values are expressed as mean ± standard deviation